DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
BioMarin - 2 Andrew Leavitt - 1 Pfizer - 1 Cory Kasimov - 1 Kasimov - 1 We've - 1 Neurocrine - 1 — CNBC's Michael Bloom - 1
Top related locs:
U.S — BioMarin San Rafael , California West Palm Beach , Florida New York Europe California
Top related orgs:
BioMarin Pharmaceutical - 2 Thomson - 2 Pfizer - 1 Sangamo Therapeutics - 1 BioMarin - 1 ISI - 1 Biotech - 1 P Biotech - 1

Search resuls for: "Roctavian"


8 mentions found


☆ Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
  + stars: | 2024-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. Without enough of that protein, the blood cannot clot properly, increasing the risk of spontaneous bleeding and severe bleeding after surgery. Pfizer said its one-time treatment significantly cut the number of annual bleeding episodes in patients with moderately severe to severe hemophilia A after 15 months. If approved, Pfizer's therapy will compete with BioMarin Pharmaceutical 's one-time treatment Roctavian. BioMarin is reportedly considering whether to divest its hemophilia A therapy, which costs $2.9 million.
Persons: Andrew Leavitt, Pfizer Organizations: Pfizer, Sangamo Therapeutics, BioMarin Locations: U.S
☆ Evercore ISI says three years of biotech underperformance may be ending, gives its 5 favorite stocks
  + stars: | 2024-05-14 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +2 min
"After 3 years of painful underperformance, winter is finally thawing and spring just might be in the air," analyst Cory Kasimov wrote in a Monday note. Biotech stocks broadly peaked in early 2021 when interest rates were at a trough, Kasimov noted. While biotech stocks are sensitive to interest rates, the analyst believes most of the group's other catalysts — such as mergers and access to capital — remain "relatively consistent." XBI YTD mountain SPDR S & P Biotech ETF performance year to date The sector is opportune for investors looking for "a stock picker's market," according to Kasimov. With this in mind, he named seven stocks to his core initial list, which he named "The Magnificent Seven."
Persons: Cory Kasimov, Kasimov, We've, Neurocrine, — CNBC's Michael Bloom Organizations: ISI, Biotech, P Biotech, Moderna Locations: —
☆ Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources
  + stars: | 2023-11-07 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +3 min
NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical (BMRN.O) and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter. Elliott declined to comment, while a representative for BioMarin did not immediately respond to a request for comment. BioMarin shares rose 12% to $85.36 on the news in morning trading in New York on Tuesday. Prior to news of Elliott's engagement, BioMarin shares were down 24% year-to-date, significantly underperforming the iShares Biotechnology ETF (IBB.O), which is down 8.6%. Elliott also successfully pushed for drug makers Alexion Pharma (AZN.L) and Allergan (ABBV.N) to be sold.
Persons: Elliott, BioMarin, hemophilia, Jean, Jacques Bienaime, Alexander Hardy, Jefferies, Bienaime, Harvey, Richard Meier, Svea Herbst, Bayliss, Jamie Freed Organizations: Investment Management, BioMarin Pharmaceutical, Biotechnology, Alexion Pharma, Svea, Thomson Locations: BioMarin, San Rafael , California, West Palm Beach , Florida, New York
☆ 'Harder to find': Goldman Sachs names stocks with growth at a 'reasonable' price — and more
  + stars: | 2023-07-27 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +3 min
Stocks with "reasonably valued" growth are becoming harder to find — given the increasing overlap between high-growth and expensive stocks, according to Goldman Sachs. First screen The first focused on stocks with growth at a reasonable price. SolarEdge Technologies : Investors can also look for strong growth from favorable geographic and end-market exposure. "Its refreshed, modern restaurant POS [point of sale] platform and new verticals should drive market share growth," Goldman analysts wrote. "We believe margins will remain in focus through 2023 and into 2024," Goldman said.
Persons: Goldman Sachs, Goldman, Goldman's, Johnson, Michael Bloom Organizations: Technologies, SolarEdge, BioMarin Pharmaceutical, Constellation Brands Locations: Europe, U.S
☆ US FDA approves BioMarin's gene therapy for hemophilia A
  + stars: | 2023-06-29 | by ( Nathan Gomes | ) www.reuters.com   time to read: +3 min
It priced the one-time therapy, Roctavian, at $2.9 million. BioMarin said most study participants continued to respond to the gene therapy through year three and beyond, and it would continue to monitor them for 15 years. BioMarin's therapy will compete for market share with Roche's (ROG.S) Hemlibra, an antibody drug which mimics the function of the blood clotting protein missing in hemophilia A patients. In April, BioMarin cut its annual sales forecast range for Roctavian to $50 million to $100 million, from $100 million to $200 million. There are about 16,000 patients in the United States with hemophilia A in which they are missing the factor VIII clotting protein.
Persons: BioMarin, Joel Beatty, Robert W Baird, Roctavian, Beatty, Khushi Mandowara, Bhanvi Satija, Nathan Gomes, Akash Sriram, Deena Beasley, Krishna Chandra Eluri, Maju Samuel, David Gregorio Our Organizations: U.S . Food, Drug Administration, European Union, Los, Thomson Locations: U.S, California, Novato , California, hemophilia, United States, Bengaluru, Los Angeles
☆ Evercore ISI's top picks for 2023 include a tech comeback story and a car racing play
  + stars: | 2023-01-12 | by ( Michelle Fox | ) www.cnbc.com   time to read: +4 min
Finding opportunities amid the market volatility is "mission critical," and there are several to be had this year, according to Evercore ISI. The Wall Street firm is predicting an economic and earnings recession, catalyzing a "cathartic" volatility spike in 2023. "Alpha opportunities are surfacing in 2022's wreckage from inflation's breakout resulting in record tightening, catalyzing a stock/bond correlated decline. With that in mind, Evercore came up with its top stock picks for 2023. The streaming company should enjoy a comeback this year, after losing 51% in 2022, according to analyst Mark Mahaney.
☆ Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
  + stars: | 2022-12-21 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The Inflation Reduction Act provided some clarity around drug pricing that should help health-care stocks. The average price target, according to FactSet, is $62, or nearly 40% above the stock's closing price on Tuesday. Gene therapies in focus Investors will be closely watching the progress of several gene therapies, according to Phipps. "Yes, these are expensive therapies," Phipps said.
☆ A top Wall Street analyst names 6 major events that could send biotech stocks soaring between now and the end of 2022
  + stars: | 2022-11-14 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +5 min
Cantor Fitzgerald analysts named six big events to mark on your calendar. While the majority of the expected events are set to come from smaller biotech companies, bigger companies — like Roche, Gilead, and Alnylam — have their own events coming through the pipeline. Here are the six major events from big biotech companies that could send stocks soaring:1. Cantor Fitzgerald analysts give Gilead's stock a neutral rating and they have an overweight rating on Arcus. Lenacapavir "could become a much bigger piece of the HIV growth narrative over the next few years," according to Cantor Fitzgerald analysts.
0 next >>
Total: 8